L
Lluís Puig
Researcher at Autonomous University of Barcelona
Publications - 510
Citations - 16811
Lluís Puig is an academic researcher from Autonomous University of Barcelona. The author has contributed to research in topics: Psoriasis & Medicine. The author has an hindex of 56, co-authored 427 publications receiving 13381 citations. Previous affiliations of Lluís Puig include Jikei University School of Medicine & Pompeu Fabra University.
Papers
More filters
Journal ArticleDOI
Secukinumab in plaque psoriasis--results of two phase 3 trials.
Richard G. Langley,Boni E. Elewski,Mark Lebwohl,Kristian Reich,Christopher E.M. Griffiths,Kim A. Papp,Lluís Puig,Hidemi Nakagawa,Lynda Spelman,Bárður Sigurgeirsson,Enrique Rivas,Tsen-Fang Tsai,Norman Wasel,Stephen K. Tyring,Thomas Salko,Isabelle Hampele,Marianne Notter,Alexander Karpov,Silvia Helou,Charis Papavassilis +19 more
TL;DR: Secukinumab was effective for psoriasis in two randomized trials, validating interleukin-17A as a therapeutic target and the rates of infection were higher with secuk inumab than with placebo in both studies and were similar to those with etanercept.
Journal ArticleDOI
Efficacy and safety of ustekinumab in patients with active psoriatic arthritis: 1 year results of the phase 3, multicentre, double-blind, placebo-controlled PSUMMIT 1 trial
Iain B. McInnes,Arthur Kavanaugh,Alice B. Gottlieb,Lluís Puig,Proton Rahman,Christopher T. Ritchlin,Carrie Brodmerkel,Shu Li,Y. Wang,Alan M. Mendelsohn,Mittie K. Doyle +10 more
TL;DR: Ustekinumab significantly improved active psoriatic arthritis compared with placebo, and might offer an alternative therapeutic mechanism of action to approved biological treatments.
Journal ArticleDOI
Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis
Mark Lebwohl,Bruce Strober,Alan Menter,Kenneth B. Gordon,Jolanta Weglowska,Lluís Puig,Kim A. Papp,Lynda Spelman,Darryl Toth,Francisco A. Kerdel,April W. Armstrong,Georg Stingl,Alexa B. Kimball,Hervé Bachelez,Jashin J. Wu,Jeffrey J. Crowley,Richard G. Langley,Tomasz Blicharski,Carle Paul,Jean-Philippe Lacour,Stephen K. Tyring,Leon H Kircik,Sergio Chimenti,Kristina Callis Duffin,Jerry Bagel,John Koo,Gary Aras,Joanne Li,Wenjie Song,Cassandra E Milmont,Yifei Shi,Ngozi Erondu,Paul Klekotka,Brian L Kotzin,Ajay Nirula +34 more
TL;DR: Bdalumab treatment resulted in significant clinical improvements in patients with moderate-to-severe psoriasis, and was found to be superior to placebo at week 12 with respect to a 100% reduction in PASI score (PASI 100).
Journal ArticleDOI
Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicentre, double-blind, placebo-controlled, randomised PSUMMIT 2 trial
Christopher T. Ritchlin,Proton Rahman,Arthur Kavanaugh,Iain B. McInnes,Lluís Puig,Shu Li,Y. Wang,Yaung-Kaung Shen,Mittie K. Doyle,Alan M. Mendelsohn,Alice B. Gottlieb +10 more
TL;DR: The interleukin-12/23 inhibitor ustekinumab (45/90 mg q12 weeks) yielded significant and sustained improvements in PsA signs/symptoms in a diverse population of patients with active PsA, including anti-TNF-experienced PsA patients.
Journal ArticleDOI
Epidemiology of atopic dermatitis in adults: Results from an international survey.
Sébastien Barbarot,S. Auziere,Abhijit Gadkari,Giampiero Girolomoni,Lluís Puig,Eric L. Simpson,David J. Margolis,M S de Bruin-Weller,Laurent Eckert +8 more
TL;DR: There are gaps in the authors' knowledge of the prevalence of adult atopic dermatitis (AD) and the need to investigate these gaps more fully.